Small Cap Feast
Small Cap Feast – 20 February 2019
Set Menu AIM:
Total number of AIM Companies (Incl Susp): 910
Total number of AIM Companies trading: 842*
* As at 18 February 2019
Set Menu NEX Growth:
Total number of NEX Growth Market Companies (Incl Susp): 89*
Total number of NEX Growth Market Companies trading: 87*
* As at 18 February 2019
Set Menu Standard List:
Total number of Standard List Companies (Incl Susp): 145*
Total number of Standard List Companies trading: 128*
* As at 18 February 2019
Dish of the Day:
No Joiners Today
No Joiners Today
Off the Menu:
No Leavers Today
No Leavers Today
Dish of the Day:
No Joiners Today
No Joiners Today
Off the Menu:
No Leavers Today
No Leavers Today
What’s Cooking in the IPO Kitchen?
Main Market (Premium)
DWF, a global legal business, expects to raise primary gross proceeds of approximately £75m. Due March
United Oil & Gas (UOG.L) an oil and gas exploration and development company brought to the Official List (Standard Segment) in July 2017 by way of a reverse takeover of Senterra Energy plc. No capital to be raised, expected market cap of £17m and expected 28 Feb
Techniplas –global producer and support services company providing highly engineered and technically complex components, making the supply chain to original equipment manufacturers more efficient. FYDec17 rev $515m.
Polemos, to be renamed Digitalbox plc, has agreed to acquire Digitalbox Publishing Holdings Limited for c.£10m through a share for share exchange. The acquisition constitutes a RTO. Polemos has also agreed to acquire the entire issued share capital of Mashed Productions Limited, a digital media business which owns the online satirical news website “The Daily Mash”, for a maximum total consideration of up to £1.2m. Market cap on admission £12.4m, expected 28 February
Integumen* (SKIN.L) 1.04p £4.21m
Integumen announced a greater than 99% reduction of bacterial growth in preliminary results of four formulations, all of which include Cannabinoid (CBD) oils, on Labskin in a range of cosmetic and skin-care treatments.
Tests, which include formulations of STOER For Men, the skin care product range owned by Integumen, were carried out on bacteria common to human skin. The bacteria tested are known to be one of the leading causes of foreign body infections with resistance to some antibiotics. “This is the first of several announcements expected over the coming weeks and months as hemp-derived CBD inclusive formulation tests extend to Labskin model systems that have disease state bacteria such as seen in acne and eczema.
As well as having an extension to the range of STOER For Men skin care products, Labskin will be offering the same test services to clients adding CBD to their skin-care and cosmetic range of products.”
McBride (MCB.L) 92.60p £237.64m
FYDec18 trading update from the leading European manufacturer and supplier of Contract Manufactured and Private Label products for the domestic Household and professional cleaning and hygiene markets. “As announced in our trading update of 10 Jan, the Group achieved good sales growth in the first half period, with continuing underlying revenues, excluding the benefit of first quarter revenues from Danlind, up 6% on the prior year.
However, the Group continues to see pressure on its cost base. We continue to expect the overall raw material pricing outlook to show improvements in the second half, but not to the extent anticipated in early Jan. In addition, distribution costs continue to rise beyond our previous estimates due to market rates and efficiency challenges driven by logistics capacity shortfalls and internal service gaps. Accordingly, although the Group continues to anticipate further good sales growth in the H2 year, the Board now expects full year adjusted PBT to be approximately 10% to 15% lower than the prior financial year.”
Impellam (IPEL.L) 555p £274.17m
De-merger of its wholly owned subsidiary, Carlisle Support Services Group Limited from the Impellam group as the next step in driving margin and EBITDA growth by focusing on its collaborative Managed Services and Specialist Staffing portfolio. The Demerger will result in qualifying shareholders being issued with an equivalent number of ordinary shares in Carlisle.
Carlisle focuses on the provision of cleaning, security, events, retail facilities and support services across the UK employing over 3,000 people. Carlisle’s vision is to be the preferred expert and the most trusted provider of people services for the customers it serves by delivering innovative, tailored solutions 24 hours a day, 7 days a week. For more information visit www.carlislesupportservices.com
For Impellam’s financial year ended 29 Dec 2017, Carlisle generated revenues of £44.8m and PBT of £0.3m. As at 29 June 2018, Carlisle had gross assets of £16.9m.
Consensus forecasts FY2018E revs of £2,281m and EBITDA of £52.5m
Eden Research (EDEN.L) 9.65p £19.17m
The Company “that develops and supplies breakthrough biopesticide products and natural microencapsulation technologies to the global crop protection, animal health and consumer products industries, announced that its commercial partner, Eastman Chemical Company, has received authorisation for Eden’s nematicide formulation, marketed as Cedroz by Eastman, from the Regulatory Affairs Directorate in Malta. Malta is acting as the zonal rapporteur Member State for the Southern EU agricultural zone and on behalf of a number of EU countries for indoor uses.
Cedroz is an innovative and natural solution designed to fight nematodes, a species that is known to cause severe damage to crops globally for both open field and greenhouse growers, resulting in yield losses and increasing farmers costs. Malta has authorised the use of Cedroz on a wide range of crops, including cucumbers, courgettes, melons, aubergine, peppers, tomatoes and strawberries.”
Collagen (COS.L) 3.75p £12.17m
“The developer and manufacturer of biomaterials and regenerative medicines for the enhancement and extension of human life, announced that it has sold its stake in Jellagen Ltd for approximately £0.215m in a private transaction.
Jellagen is a private marine biotechnology company founded in 2013 focused on developing collagen biomaterials from jellyfish. Collagen Solutions had held a minority equity position in Jellagen since 2014 and also collaborated on technology development. The transaction to sell Collagen Solutions’ shares in Jellagen followed the most recent investment round in Jellagen in which the Company did not participate.”
Bango (BGO.L) 87p £56.93m
The mobile commerce company, announced that Paul Larbey has joined Bango as COO as Bango expands its payments business to a broader mobile commerce platform offering, enabling its partners to more effectively monetize the $100bn plus app ecosystem.
Paul joins Bango following his role as CEO at Velocix, a global leader in streaming technology where he remains a NED. Paul grew Velocix from a small start-up to the world’s leading IP video streaming specialist. As CEO, Paul led the Velocix team though its integration into Alcatel-Lucent and then Nokia. In 2018 Paul orchestrated the spin out of the division from Nokia to create a pure-play streaming technology company.
Emmerson (EML.L) 2.95p £18.16m
The Company “focused on developing its low capital cost, high margin potash project in Morocco, announced the appointment of Mr Don Larmour of Global Potash Solutions to advise on metallurgy and processing.
Mr Larmour will act as a consultant for the Khemisset Potash Project Feasibility Study, which is expected to commence in the first half of 2019. The appointment of an expert of Mr Larmour’s calibre marks a significant step towards the construction of the Project.
The appointment of a consultant for the Feasibility Study follows the results of the Scoping Study, published late last year, which confirmed that Khemisset has the potential to be among the lowest capital cost, highest margin potash projects in the world. As such, its economics are outstanding, with forecasted EBITDA margins in excess of 60% and a post-tax NPV10 of over US$1.1bn based on industry expert price forecasts.”
Mobile Tornado Group (MBT.L) 3.4p £11.52m
“The leading provider of instant communication mobile applications to the enterprise market, issued a trading update ahead of the announcement of results for the year ended 31 Dec 2018. The audited results are expected to be announced in the week commencing 15 Apr 2019.
Trading in the second half of the year, and therefore for the full year, was in line with the Board’s expectations. A good trading performance during the second half has resulted in a significant improvement in adjusted EBITDA loss during this period, when compared to the first six months. As a result, subject to audit, the Board expects to report revenue and adjusted EBITDA loss for the year ended 31 Dec 2018 and net debt as at 31 Dec 2018 in line with market expectations.”
We could see no forecasts.
EKF Diagnostics (EKF.L) 35.5p £156.89m
The point-of-care business, announced that its Quo-Test analyser has received US Food and Drug Administration 510(k) clearance for professional use in a clinical laboratory setting.
The Quo-Test is a fully automated glycated haemoglobin (HbA1c) analyser, providing fast, easy and reliable HbA1c measurement for the monitoring and management of diabetes.
The FDA 510(k) clearance allows the Quo-Test to be used in a laboratory setting for in-vitro quantitative determination of HbA1c in whole blood samples.
Haydale Graphene (HAYD.L) 11.75p £6.29m
“The global advanced materials group, notes speculation regarding the prospect of an imminent equity placing. The Company confirms that it is currently conducting market soundings with potential institutional investors and that any such equity placing is expected to be carried out at a material discount to yesterday’s closing price. In line with the Company’s previous practice, it is anticipated that a pre-emptive offer would also be made to existing shareholders.
Discussions with potential investors remain ongoing and a detailed announcement will be made in due course.”
0203 764 2344
*A corporate client of Hybridan LLP
This document, which does not constitute research, has been issued by Hybridan LLP for information purposes only and should not be construed in any circumstances as an offer to sell or solicitation of any offer to buy any security or other financial instrument, nor shall it, or the fact of its distribution, form the basis of, or be relied upon in connection with, any contract relating to any such action. This document has no regard for the specific investment objectives, financial situation or needs of any specific person or entity and is not a personal recommendation to any such person or entity. Recipients should reach an individual investment decision, based upon their respective financial objectives and financial resources and, if any doubt, should seek advice from an investment advisor.
The information contained in this document is based on materials and sources that are believed to be reliable; however, such information has not been independently verified and therefore it is not possible to confirm such information as being accurate. This document is not intended to be a complete statement or summary of any securities, markets, reports or developments referred to herein. No representation or warranty, either express or implied, is made or accepted by Hybridan LLP, its members, officers, employees, agents or associated undertakings in relation to the accuracy, completeness or reliability of the information contained in this document, nor should it be relied upon as such.
The content of this document includes market commentary and other information which we have prepared in relation to the company referred to in this document, which is our broking client. The provision of this document to you constitutes a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of Regulation 600/2014/EU (MIFID II Regulation).
Any and all opinions expressed are current as of the date appearing on this face of this document only. Any and all opinions expressed are subject to change without notice and Hybridan LLP is under no obligation to update the information contained herein. To the fullest extent permitted by law, none of Hybridan LLP, its members, officers, employees, agents or associated undertakings shall have any liability whatsoever for any direct or indirect or consequential loss or damage (including lost profits) arising in any way from use of all or any part of the information in this document.
This document should not be relied upon as being an independent or impartial view of the subject matter and, for the avoidance of doubt, constitutes non-independent research (as such term is defined in the Financial Conduct Authority’s Conduct of Business Sourcebook to reflect the requirements of the MIFID II Regulation and Directive 2014/65/EU (known as MIFID II)). The individuals who prepared this document may be interested in shares in the company concerned and/or other companies within its sector, may be involved in providing other financial services to the company or companies referenced in this document or to other companies who might be said to be competitors of the company or companies referenced in this document. As a result both Hybridan LLP and the individual members, officers and/or employees who prepared this document may have responsibilities that conflict with the interests of the persons who receive this document. Hybridan LLP and/or connected persons may, from time to time, have positions in, make a market in and/or effect transactions in any investment or related investment mentioned herein and may provide financial services to the issuers of such investments.
In the United Kingdom, this document is directed at and is for distribution only to persons who (i) fall within article 19(5) (persons who have professional experience in matters relating to investments) or article 49(2) (a) to (d) (high net worth companies, unincorporated associations, etc.) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (SI 2005/1529) (as amended) or (ii) persons who are each a professional client or eligible counterparty (as those terms are defined in the Financial Conduct Authority’s Conduct of Business Sourcebook) of Hybridan LLP (all such persons referred to in (i) and (ii) together being referred to as relevant persons). This document must not be acted on or relied up on by persons who are not relevant persons. For the purposes of clarity, this document is not intended for and should not be relied upon by any person who would be classified as a retail client under the Financial Conduct Authority’s Conduct of Business Sourcebook.
Neither this document, nor any copy of part thereof may be distributed in any other jurisdictions where its distribution may be restricted by law and persons into whose possession this document comes should inform themselves about, and observe, any such restrictions. Distribution of this report in any such other jurisdictions may constitute a violation of territorial and/or extra-territorial securities laws, whether in the United Kingdom, the United States or any other jurisdiction in any part of the world.
Where possible this document is made available to all relevant recipients at the same time. Dissemination of research by Hybridan LLP is monitored to ensure that it is only provided to relevant persons. Research prepared by Hybridan LLP is not intended to be received and/or used by any person who is a retail client.
Hybridan LLP and/or its associated undertakings may from time-to-time provide investment advice or other services to, or solicit such business from, any of the companies referred to in this document. Accordingly, information may be available to Hybridan LLP that is not reflected in this material and Hybridan LLP may have acted upon or used the information prior to or immediately following its publication. In addition, Hybridan LLP, the members, officers and/or employees thereof and/or any connected persons may have an interest in the securities, warrants, futures, options, derivatives or other financial instrument of any of the companies referred to in this document and may from time-to-time add or dispose of such interests.
This document may not be copied, redistributed, resent, forwarded, disclosed or duplicated in any form or by any means, whether in whole or in part other than with the prior written consent of Hybridan LLP.
MIFID II status of Hybridan LLP research
The cost of production of our corporate research is met by retainers from our corporate broking clients. In addition, from time to time we issue further communications as market commentary (such as our daily newsletter, Small Cap Breakfast), which we consider to constitute a minor non-monetary benefit which is capable of enhancing the quality of service provided by Hybridan LLP and which is of a scale and nature which could not be judged to impair the duty of Hybridan LLP to act in the best interest of its client falling within article 24(7)(b) of the MIFID II Regulation.
Hybridan LLP is a limited liability partnership registered in England and Wales, registered number OC325178, and is authorised and regulated by the Financial Conduct Authority and is a member of the London Stock Exchange. Any reference to a partner in relation to Hybridan LLP is to a member of Hybridan LLP or an employee with equivalent standing and qualifications. A list of the members of Hybridan LLP is available for inspection at the registered office, 2 Jardine House, The Harrovian Business Village, Bessborough Road, Harrow, Middlesex HA1 3EX.
If you would like to unsubscribe, please email email@example.com with “unsubscribe me”.